Pharmacy

Your Article Summary

See Latest Articles

Bayer Schering Pharma presents positive results of phase II study with Riociguat
BayNews International, 05/20/09

Positive data from a phase II trial with Bayer Schering Pharma's oral agent riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension were presented today at the American Thoracic Society international conference in San Diego, USA. Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase stimulators and is being investigated as a new approach for the treatment of different forms of pulmonary hypertension.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

 See all of Drug Trials

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

In vitro Growth Inhibitory Activity and Malaria Risk in a Cohort Study in Mali
Infection and Immunity, 12/02/09

A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09

Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09

 See all of Major Studies